The Federal Circuit has confirmed a decision by the Patent Trial and Appeal Board (PTAB), as detailed in a recent Law360 report. This decision involves the invalidation of claims in a patent held by Shilpa Pharma Inc. The patent, previously contested, accused Novartis Pharmaceuticals Corp. of infringement concerning its multiple sclerosis medication.
The ruling was articulated through a concise one-word order, maintaining the PTAB’s position. This decision represents a significant point in the ongoing legal discourse between Shilpa Pharma and Novartis regarding patent rights and pharmaceutical innovation.